Blake Borgeson, Director at RECURSION PHARMACEUTICALS, INC. (RXRX), sold 22,894 shares at $6.22 ($142K) on 2024-10-01, disclosed to the SEC on 2024-10-03.
Scheduled sale ($142k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.22 | 11,447 | $71K | 50.0% |
| 2 | $6.22 | 11,447 | $71K | 50.0% |
| Total | $6.22 avg | 22,894 | $142K | 100% |
| Filing → |
| RXRX | SELL | 2026-07-09 | $159K | — | Filing → |
| RXRX | SELL | 2026-06-04 | $110K | — | Filing → |
| RXRX | SELL | 2026-05-07 | $106K | — | Filing → |